Predictive Oncology (POAI) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 05, 2021
Document Information [Line Items]
Entity Central Index Key	0001446159
Entity Registrant Name	Predictive Oncology Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-36790
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-1007393
Entity Address, Address Line One	2915 Commers Drive, Suite 900
Entity Address, City or Town	Eagan
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55121
City Area Code	651
Local Phone Number	389-4800
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	POAI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		65,576,334

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets:
Cash and Cash Equivalents	$ 41,771,515	$ 678,332
Accounts Receivable	275,193	256,878
Inventories	397,976	289,535
Prepaid Expense and Other Assets	595,224	289,490
Total Current Assets	43,039,908	1,514,235
Fixed Assets, net	3,810,640	3,822,700
Intangibles, net	3,199,047	3,398,101
Lease Right-of-Use Assets	961,419	1,395,351
Other Long-Term Assets	179,096	116,257
Goodwill	0	2,813,792
Total Assets	51,190,110	13,060,436
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable	1,029,545	1,372,070
Notes Payable – Net of Discounts of $0 and $244,830	0	4,431,925
Accrued Expenses and Other Liabilities	940,892	2,588,047
Derivative Liability	225,498	294,382
Deferred Revenue	152,546	53,028
Lease Liability	637,352	597,469
Total Current Liabilities	2,985,833	9,336,921
Lease Liability – Net of current portion	388,473	845,129
Other Long-term Liabilities	30,898	235,705
Total Liabilities	3,405,204	10,417,755
Stockholders’ Equity:
Common Stock, $.01 par value, 200,000,000 and 100,000,000 shares authorized, 65,457,484 and 19,804,787 outstanding	654,575	198,048
Additional Paid-in Capital	167,413,309	110,826,949
Accumulated Deficit	(120,283,770)	(108,383,108)
Total Stockholders’ Equity	47,784,906	2,642,681
Total Liabilities and Stockholders’ Equity	51,190,110	13,060,436
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding	$ 792	$ 792

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Discount of note payable	$ 0	$ 244,830
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	100,000,000
Common stock, shares outstanding (in shares)	65,457,484	19,804,787
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	2,300,000	2,300,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares outstanding (in shares)	79,246	79,246

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue		$ 313,663	$ 480,757	$ 944,187	$ 958,484
Cost of goods sold		110,165	175,206	350,800	353,124
Gross profit		203,498	305,551	593,387	605,360
General and administrative expense		2,061,458	2,226,634	7,410,208	8,266,927
Operations expense		648,935	568,766	1,791,543	1,638,635
Sales and marketing expense		172,869	121,514	447,298	518,938
Loss on goodwill impairment		2,813,792	2,997,000	2,813,792	2,997,000
Total operating loss		(5,493,556)	(5,608,363)	(11,869,454)	(12,816,140)
Other income		58,830	44,926	144,122	97,894
Other expense		(7,413)	(2,147,057)	(244,214)	(3,993,969)
Gain on derivative instruments		4,122	1,402,768	68,884	1,007,794
Gain on notes receivables associated with asset purchase		0	0	0	1,290,000
Net loss		(5,438,017)	(6,307,726)	(11,900,662)	(14,414,421)
Deemed dividend		0	554,287	0	554,287
Net loss attributable to common shareholders		$ (5,438,017)	$ (6,862,013)	$ (11,900,662)	$ (14,968,708)
Loss per common share basic and diluted (in dollars per share)		$ (0.08)	$ (0.46)	$ (0.23)	$ (1.51)
Weighted average shared used in computation - basic (in shares)	[1]	65,406,312	15,026,789	51,272,960	9,935,738
[1]	The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive:

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Registered Direct Offerings [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Private Placement [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Registered Direct Offering [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Conversion of Series D Preferred Stock to Common Stock [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Series E Preferred Stock Conversions [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Conversion of Series E Preferred Stock [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Common Stock [Member]New Warrants From Exercise of Warrants [Member]	Common Stock [Member]Prefunded Warrants [Member]	Common Stock [Member]Registered Direct Offerings [Member]	Common Stock [Member]Private Placement [Member]	Common Stock [Member]Registered Direct Offering [Member]	Common Stock [Member]May 2020 Offering [Member]	Common Stock [Member]Bridge Notes [Member]	Common Stock [Member]Series E Preferred Stock Conversions [Member]	Common Stock [Member]Conversion of Series E Preferred Stock [Member]	Common Stock [Member]Conversion of Series D Preferred Stock to Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]New Warrants From Exercise of Warrants [Member]	Additional Paid-in Capital [Member]June 2020 Warrant [Member]	Additional Paid-in Capital [Member]Prefunded Warrants [Member]	Additional Paid-in Capital [Member]Registered Direct Offerings [Member]	Additional Paid-in Capital [Member]Private Placement [Member]	Additional Paid-in Capital [Member]Registered Direct Offering [Member]	Additional Paid-in Capital [Member]May 2020 Offering [Member]	Additional Paid-in Capital [Member]Bridge Notes [Member]	Additional Paid-in Capital [Member]Series E Preferred Stock Conversions [Member]	Additional Paid-in Capital [Member]Conversion of Series E Preferred Stock [Member]	Additional Paid-in Capital [Member]Conversion of Series D Preferred Stock to Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]Registered Direct Offerings [Member]	Retained Earnings [Member]Private Placement [Member]	Retained Earnings [Member]Registered Direct Offering [Member]	Retained Earnings [Member]	New Warrants From Exercise of Warrants [Member]	June 2020 Warrant [Member]	Prefunded Warrants [Member]	Registered Direct Offerings [Member]	Private Placement [Member]	Registered Direct Offering [Member]	May 2020 Offering [Member]	Bridge Notes [Member]	Conversion of Series E Preferred Stock [Member]	Conversion of Series D Preferred Stock to Common Stock [Member]	Total
Balance (in shares) at Dec. 31, 2019				79,246		3,500,000			258											4,056,652
Balance at Dec. 31, 2019				$ 792		$ 35,000			$ 3											$ 40,567												$ 93,653,667				$ (82,498,711)											$ 11,231,318
Shares issued pursuant to agreement with former CEO related to accrued interest (in shares)																				50,000
Shares issued pursuant to agreement with former CEO related to accrued interest																				$ 500												129,500															130,000
Shares issued pursuant to convertible debt, Shares (in shares)																170,000	141,191
Shares issued pursuant to convertible debt																$ 1,700	$ 1,412											$ 265,628	$ (1,411)															$ 267,328
Net loss																																				(4,529,317)											(4,529,317)
Shares issued pursuant to Equity Line (in shares)																				943,000
Shares issued pursuant to Equity Line																				$ 9,430												1,860,469															1,869,899
Inducement shares issued pursuant to promissory note extension (in shares)																				30,000
Inducement shares issued pursuant to promissory note extension																				$ 300												40,950															41,250
Issuance of shares and prefunded warrants pursuant to March 2020 private placement (in shares)																				260,000
Issuance of shares and prefunded warrants pursuant to March 2020 private placement																				$ 2,600												455,223															457,823
Inducement shares issued pursuant to 2020 convertible debt and warrants (in shares)																				46,875
Inducement shares issued pursuant to 2020 convertible debt and warrants																				$ 468												119,532															120,000
Warrants issued pursuant to 2020 convertible debt																																116,951															116,951
Shares issued pursuant to conversions (in shares)							(50)
Shares issued pursuant to conversions							$ (1)
Shares issued to consultant and other (in shares)																				155,000
Shares issued to consultant and other																				$ 1,550												360,750															362,300
Vesting expense																																287,838															287,838
Balance (in shares) at Mar. 31, 2020				79,246		3,500,000			208											5,852,718
Balance at Mar. 31, 2020				$ 792		$ 35,000			$ 2											$ 58,527												97,289,097				(87,028,028)											10,355,390
Balance (in shares) at Dec. 31, 2019				79,246		3,500,000			258											4,056,652
Balance at Dec. 31, 2019				$ 792		$ 35,000			$ 3											$ 40,567												93,653,667				(82,498,711)											11,231,318
Net loss																																															(14,414,421)
Shares issued pursuant to conversions																																													$ (3)	$ (35,000)
Balance (in shares) at Sep. 30, 2020				79,246																16,593,283
Balance at Sep. 30, 2020				$ 792																$ 165,932												108,983,174				(96,913,132)											12,236,766
Balance (in shares) at Mar. 31, 2020				79,246		3,500,000			208											5,852,718
Balance at Mar. 31, 2020				$ 792		$ 35,000			$ 2											$ 58,527												97,289,097				(87,028,028)											10,355,390
Shares issued pursuant to agreement with former CEO related to accrued interest (in shares)																				1,533,481
Shares issued pursuant to agreement with former CEO related to accrued interest																				$ 15,335												2,177,543															2,192,878
Issuance of shares and warrants (in shares)															1,396,826
Issuance of shares and warrants															$ 13,968												$ 591,949																$ 605,917
Exercise of warrants (in shares)										1,274,826	1,390,166
Exercise of warrants										$ 12,748	$ 13,902										$ 1,682,237		$ (13,148)														$ 1,694,985		$ 754
Shares issued pursuant to convertible debt, Shares (in shares)					(3,500,000)													1,257,416	350,004
Shares issued pursuant to convertible debt					$ (35,000)													$ 12,574	$ 3,500											$ (12,572)	$ 31,500
Vesting expense																				$ 204												34,796															35,000
Net loss																																				(3,577,378)											(3,577,378)
Vesting expense, net of repurchases of common stock upon vesting of restricted stock units (in shares)																				20,350
Warrants issued pursuant to 2020 convertible debt																																62,373															62,373
Shares issued pursuant to conversions (in shares)								(208)
Shares issued pursuant to conversions								$ (2)
Vesting expense																																134,939															134,939
Shares issued in connection with asset purchase agreement (in shares)																				115,000
Shares issued in connection with asset purchase agreement																				$ 1,150												185,150															186,300
Balance (in shares) at Jun. 30, 2020				79,246																13,190,787
Balance at Jun. 30, 2020				$ 792																$ 131,908												102,163,864				(90,605,406)											11,691,158
Exercise of warrants (in shares)																				122,000
Exercise of warrants																				$ 1,220												190,930															192,150
Vesting expense																				$ 161												23,839															24,000
Net loss																																				(6,307,726)											(6,307,726)
Shares issued pursuant to Equity Line (in shares)																				2,307,000
Shares issued pursuant to Equity Line																				$ 23,070												2,336,733															2,359,803
Vesting expense, net of repurchases of common stock upon vesting of restricted stock units (in shares)																				16,108
Shares issued to consultant and other (in shares)																				2,669
Shares issued to consultant and other																				$ 26												3,005															3,031
Shares issued in connection with asset purchase agreement (in shares)																				954,719
Shares issued in connection with asset purchase agreement																				$ 9,547												1,460,720															1,470,267
Repricing and Reclassification of warrants issued pursuant to convertible debt																						$ 803,455										1,865,953						$ 803,455									1,865,953
Vesting expense and option repricing																																134,675															134,675
Balance (in shares) at Sep. 30, 2020				79,246																16,593,283
Balance at Sep. 30, 2020				$ 792																$ 165,932												108,983,174				(96,913,132)											12,236,766
Balance (in shares) at Dec. 31, 2020				79,246																19,804,787
Balance at Dec. 31, 2020				$ 792																$ 198,048												110,826,949				(108,383,108)											2,642,681
Shares issued pursuant to agreement with former CEO related to accrued interest (in shares)																				100,401
Shares issued pursuant to agreement with former CEO related to accrued interest																				$ 1,004												142,569															143,573
Issuance of shares and warrants (in shares)												13,488,098	9,043,766
Issuance of shares and warrants												$ 134,881	$ 90,438											$ 14,877,611	$ 15,974,301															$ 15,012,492	$ 16,064,739
Exercise of warrants (in shares)																				5,247,059
Exercise of warrants																				$ 52,471												4,442,799															4,495,270
Shares issued pursuant to convertible debt, Shares (in shares)																				1,107,544
Shares issued pursuant to convertible debt																				$ 11,075												502,936															514,011
Shares issued to consultant & other (in shares)																				2,665
Shares issued to consultant & other																				$ 27												(4,075)															(4,048)
Vesting expense																																565,082															565,082
Net loss																																				(3,888,713)											(3,888,713)
Balance (in shares) at Mar. 31, 2021				79,246																48,794,320
Balance at Mar. 31, 2021				$ 792																$ 487,944												147,328,172				(112,271,821)											35,545,087
Balance (in shares) at Dec. 31, 2020				79,246																19,804,787
Balance at Dec. 31, 2020				$ 792																$ 198,048												110,826,949				(108,383,108)											2,642,681
Net loss																																															(11,900,662)
Shares issued pursuant to conversions																																													$ 0	$ 0
Balance (in shares) at Sep. 30, 2021				79,246																65,457,484
Balance at Sep. 30, 2021				$ 792																$ 654,575												167,413,309				(120,283,770)											47,784,906
Balance (in shares) at Mar. 31, 2021				79,246																48,794,320
Balance at Mar. 31, 2021				$ 792																$ 487,944												147,328,172				(112,271,821)											35,545,087
Shares issued pursuant to agreement with former CEO related to accrued interest (in shares)																				400,000
Shares issued pursuant to agreement with former CEO related to accrued interest																				$ 4,000												(4,000)															0
Issuance of shares and warrants (in shares)														15,520,911
Issuance of shares and warrants														$ 155,209												$ 19,291,087																$ 19,446,296
Shares issued to consultant & other (in shares)																				47,424
Shares issued to consultant & other																				$ 474												48,328															48,802
Vesting expense																																33,243															33,243
Net loss																																				(2,573,932)											(2,573,932)
Shares issued pursuant to Equity Line (in shares)																				572,504
Shares issued pursuant to Equity Line																				$ 5,725												582,865															588,590
Balance (in shares) at Jun. 30, 2021				79,246																65,335,159
Balance at Jun. 30, 2021				$ 792																$ 653,352												167,279,695				(114,845,753)											53,088,086
Exercise of warrants (in shares)																				22,000
Exercise of warrants																				$ 220												18,370															18,590
Shares issued to consultant & other (in shares)																				77,191
Shares issued to consultant & other																				$ 772												97,997															98,769
Vesting expense																				231												17,247															17,478
Net loss																																				(5,438,017)											(5,438,017)
Vesting expense, net of repurchases of common stock upon vesting of restricted stock units (in shares)																				23,134
Balance (in shares) at Sep. 30, 2021				79,246																65,457,484
Balance at Sep. 30, 2021				$ 792																$ 654,575												$ 167,413,309				$ (120,283,770)											$ 47,784,906

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	2 Months Ended	3 Months Ended					9 Months Ended		12 Months Ended
	Feb. 28, 2021	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash flow from operating activities:
Net loss		$ (5,438,017)	$ (3,888,713)		$ (6,307,726)	$ (4,529,317)	$ (11,900,662)	$ (14,414,421)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization							970,488	716,595
Vesting expense							627,329	557,452
Amortization of debt discount							244,830	996,271
Gain on valuation of equity-linked instruments and derivative liability							(68,884)	(1,007,794)
Debt extinguishment costs							0	1,996,681
Equity instruments issued in connection with 2020 convertible debt							0	20,695
Equity instruments issued for management, consultant, and other							143,523	424,331
Gain on note receivable in connection with asset purchase		0			0		0	(1,290,000)
Loss on fixed asset disposal							5,858	120,577
Loss on goodwill impairment		2,813,792		$ 9,879,458	2,997,000		2,813,792	2,997,000	$ 12,876,498	$ 8,100,000
Changes in assets and liabilities:
Accounts receivable							(18,315)	(122,003)
Inventories							(108,441)	(15,752)
Prepaid expense and other assets							(313,573)	(109,060)
Accounts payable							(342,525)	(1,438,033)
Accrued expenses							(412,952)	587,937
Deferred revenue							99,518	25,739
Other long-term liabilities							(204,807)	0
Net cash provided by operating activities:							(8,464,821)	(9,953,785)
Cash flow from investing activities:
Purchase of fixed assets							(714,534)	(114,180)
Proceeds from asset sales							0	133,850
Loan activities							(55,000)	0
Acquisition of intangibles							(50,699)	(45,862)
Net cash used in investing activities:							(820,233)	(26,192)
Cash flow from financing activities:
Proceeds from issuance of common stock, net							50,523,527	0
Proceeds from debt issuance							0	2,761,867
Proceeds from exercise of warrants into common stock							4,513,860	1,935,854
Repayment of debt							(4,162,744)	(1,459,973)
Proceeds from issuance of common stock pursuant to equity line							588,590	4,229,702
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs	$ 31,077,231							5,057,919
Payment penalties							(1,073,470)	(247,327)
Repurchase of common stock upon vesting of restricted stock units							(11,526)	0
Other financing (security deposit)							0	25,416
Net cash used in financing activities:							50,378,237	12,303,458
Net increase in cash and cash equivalents							41,093,183	2,323,481
Cash and cash equivalents at the beginning of period	$ 678,332		$ 678,332	2,474,312		$ 150,831	678,332	150,831	150,831
Cash at the end of period		$ 41,771,515		$ 678,332	$ 2,474,312		41,771,515	2,474,312	$ 678,332	$ 150,831
Non-cash transactions:
Bridge loan conversion into common stock							$ 0	$ 267,328
Shares issued pursuant to former CEO note conversion and accrued interest and exchange agreement (in shares)							0	2,322,878
Shares issued pursuant to former CEO per agreement related to accrued interest							$ 143,573	$ 0
Fixed assets sold for accounts receivable							0	89,207
Put and conversion derivative from debt issuance and modifications							0	636,563
Inducement shares issued pursuant to convertible debt							514,011	140,555
Fixed assets acquired from common stock							0	1,470,267
Increase to operating lease right of use asset and lease liability due to new and modified leases							0	1,417,076
Warrants issued pursuant to debt issuance							0	179,324
Fixed assets acquired for notes receivable and common stock							0	1,492,500
Cash paid during period for:
Interest paid on debt							695,989	144,791
Conversion of Series E Preferred Stock [Member]
Non-cash transactions:
Preferred stock conversions							0	3
Conversion of Series D Preferred Stock to Common Stock [Member]
Non-cash transactions:
Preferred stock conversions							$ 0	$ 35,000

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations and Continuance of Operations Predictive Oncology Inc. (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 13, 2019. The Company operates in three In addition, the Company’s wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), is developing the next generation, patient-derived tumor models for precision cancer therapy and drug development. TumorGenesis is presented as part of the condensed consolidated financial statements and is included in corporate in the Company’s segment reporting. During the first 2018, April 4, 2019, The Company had cash and cash equivalents of $41,771,515 as of September 30, 2021. September 30, 2021, October 2019, three September 30, 2021, In June 2021, 6 In January February 2021, March 1, 2021, September 2018, September 2019, February 2020 2021 6 The Company believes that its existing capital resources will be sufficient to support its operating plan for the next twelve may twelve Coronavirus Outbreak In March 2020, 19 not 19 19 2020 may 2020. fourth 2020, 19 may Interim Financial Statements The Company has prepared the condensed consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim condensed consolidated financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations, and its cash flows for the interim periods. These interim condensed consolidated financial statements reflect all intercompany eliminations. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto contained in the Annual Report on Form 10 March 15, 2021. may not Accounting Policies and Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates. Reclassifications Certain reclassifications have been made to the prior years’ condensed consolidated financial statements to conform to the current year presentation. The reclassifications had no Cash and cash equivalents The Company considers all highly liquid instruments with maturities when purchased of three Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the status of individual accounts. Amounts recorded in accounts receivable on the condensed consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance for doubtful accounts is maintained to provide for the estimated amount of receivables that will not 30 30 not September 30, 2021 December 31, 2020. Fair Value Measurements As outlined in Accounting Standards Codification (“ASC”) 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 7 Derivatives Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first Fixed Assets Fixed assets are stated at cost less accumulated depreciation and amortization. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers, software, and office equipment 3 - 10 Leasehold improvements (1) 2 - 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 10 Demo equipment 3 ( 1 Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term. Upon retirement or sale of fixed assets, the cost and related accumulated depreciation or amortization are removed from the condensed consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred. Long-lived Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. Accumulated amortization is included in intangibles, net in the accompanying condensed consolidated balance sheets. The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment may not may not not The Company concluded there was no December 31, 2020. September 30, 2020. The Company concluded there was no impairment of its finite-lived assets as of December 31, 2020. 360. The Company concluded there was no September 30, 2021. 360. Goodwill In accordance with ASC 350, Intangibles Goodwill and Other not December 31, may not To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first not may first 2017 04, Simplifying the Test for Goodwill Impairment 3 1 Note 4 Intangible Assets and Goodwill Leases ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 not The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms. Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within the Skyline segment. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping, and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the Skyline reportable segment. Revenue from Clinical Testing The Precision Oncology Insights are clinical diagnostic testing comprised of the Company’s Tumor Drug Response Testing (formerly ChemoFx) and Genomic Profiling (formerly BioSpeciFx) tests. The Tumor Drug Response test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the Genomic Profiling test evaluates the expression of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics’ payment terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at one For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect less consideration than it originally estimated for a contract with a patient, it will account for the change as a decrease to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. Accounts receivable totaled $275,193 and $256,878 as of September 30, 2021 December 31, 2020, The Company’s deferred revenues related primarily to maintenance plans of $152,546 and $53,028 as of September 30, 2021 December 31, 2020, Practical Expedients The Company has elected the practical expedient not Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility, and estimated term. The fair value of each option and warrant grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: For the nine months ended September 30, 2021 2020 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% - 89.6% 82.6% - 87% Risk-free interest rate 0.93% - 1.45% 0.13% - 1.78% Expected life (in years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% - 89.6% 82.6%-87% Risk-free interest rate 0.42% - 1.04% 0.135% - 0.79% Expected life (in years) 3 - 5.5 5 - 5.5 Research and Development Research and development costs are charged to operations as incurred. Research and development costs were $234,357 and $227,805 for the nine September 30, 2021 2020, Other Expense Other expense consisted primarily of interest expense, payment premium, amortization of original issue discounts, and loss on debt extinguishment associated with the Company’s notes payable. Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering unless such costs are deemed to be insignificant in which case they are expensed as incurred. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes 740” 740, There is no income tax provision in the accompanying condensed consolidated statements of net loss due to the cumulative operating losses that indicate a 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not Under Internal Revenue Code Section 382, may not not 382 may Tax years subsequent to 2017 Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one zero Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no In June 2016, 2016 13, not 12b 2 1934, January 1, 2023.

Note 2 - Inventories

Note 2 - Inventories	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 2 INVENTORIES Inventory balances are as follows: As of September 30, 2021 As of December 31, 2020 Finished goods $ 222,898 $ 95,898 Raw materials 161,910 151,366 Work-In-Process 13,168 42,271 Total $ 397,976 $ 289,535

Note 3 - Fixed Assets

Note 3 - Fixed Assets	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 3 FIXED ASSETS The Company’s fixed assets consist of the following: As of September 30, 2021 As of December 31, 2020 Computers, software, and office equipment $ 1,964,329 $ 1,862,669 Leasehold improvements 321,796 315,297 Laboratory equipment 3,402,586 2,811,012 Manufacturing tooling 108,955 108,955 Demo equipment 56,614 56,614 Total 5,854,280 5,154,547 Less: Accumulated depreciation and amortization (2,043,640 ) (1,331,847 ) Total Fixed Assets, Net $ 3,810,640 $ 3,822,700 Depreciation expense was $720,736 and $485,648 during the nine September 30, 2021 2020, three September 30, 2021 2020,

Note 4 - Intangible Assets

Note 4 - Intangible Assets	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 4 INTANGIBLE ASSETS AND GOODWILL The components of intangible assets were as follows: As of September 30, 2021 As of December 31, 2020 Gross Carrying Costs Accumulated Amortization Net Carrying Amount Gross Carrying Costs Accumulated Amortization Net Carrying Amount Patents & Trademarks $ 452,119 $ (225,182 ) $ 226,937 $ 401,421 $ (211,110 ) $ 190,311 Developed Technology 2,882,000 (360,249 ) 2,521,751 2,882,000 (252,175 ) 2,629,825 Customer Relationships 445,000 (370,833 ) 74,167 445,000 (259,583 ) 185,417 Tradename 398,000 (21,808 ) 376,192 398,000 (5,452 ) 392,548 Total $ 4,177,119 $ (978,072 ) $ 3,199,047 $ 4,126,421 $ (728,320 ) $ 3,398,101 Amortization expense was $249,752 and $230,947 during the nine September 30, 2021 2020, three September 30, 2021 2020, The following table outlines the estimated future amortization expense related to intangible assets held as of September 30, 2021: Year ending December 31, Expense 2021 $ 83,940 2022 224,511 2023 187,428 2024 187,428 2025 187,428 Thereafter 2,328,312 Total $ 3,199,047 Goodwill In accordance with ASC 350, Intangibles Goodwill and Other not In the Helomics acquisition, the Company recorded goodwill of $23,790,290. The goodwill was recorded to the Helomics segment which represents a single reporting unit. The Company’s annual impairment test as of December 31, 2019 During the third 2020, September 30, 2020, In testing goodwill for impairment as of September 30, 2020, September 30, 2020. September 30, 2020 When evaluating the fair value of Helomics reporting unit as of September 30, 2020, In testing goodwill for impairment as of December 31, 2020, December 31, 2020. December 31, 2020 When evaluating the fair value of Helomics reporting unit the Company used a discounted cash flow model. Key assumptions used to determine the estimated fair value as of December 31, 2020 The following tables present changes in the carrying value of goodwill our consolidated balance sheet through December 31, 2020: Goodwill balance at December 31, 2018 $ - Acquired 23,790,290 Impairment (8,100,000 ) Goodwill balance at December 31, 2019 $ 15,690,290 Impairment (12,876,498 ) Goodwill balance at December 31, 2020 $ 2,813,792 During the third 2021, In testing goodwill for impairment as of September 30, 2021, September 30, 2021. The quantitative review as of September 30, 2021 September 30, 2021, Goodwill balance at December 31, 2020 $ 2,813,792 Impairment (2,813,792 ) Goodwill balance at September 30, 2021 $ - When evaluating the fair value of Helomics reporting unit the Company used a discounted cash flow model and market comparisons. Key assumptions used to determine the estimated fair value included: (a) expected cash flow for the 10-year period following the testing date (including net revenues, costs of revenues, and operating expenses as well as estimated working capital needs and capital expenditures); (b) an estimated terminal value using a terminal year growth rate of 4.0% determined based on the growth prospects of the reporting unit; and (c) a discount rate of 15% based on management’s best estimate of the after-tax weighted average cost of capital. The Company further used a probability weighting of various forecasts to address forecast risk. The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 1 not

Note 5 - Notes Payable

Note 5 - Notes Payable	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 5 NOTES PAYABLE The balances of notes payable were as follows: Due Date As of September 30, 2021 As of December 31, 2020 Promissory note 2019 March 31, 2021 $ - $ 1,490,833 Promissory note 2020 March 31, 2021 - 1,464,146 2018 Investor Loan March 31, 2021 - 1,721,776 Total Notes Payable, gross - 4,676,755 Less: Unamortized discount - (244,830 ) Total Notes Payable, net $ - $ 4,431,925 Promissory Note Conversions Each investor received the right to convert all or any part of its 2018 may March 31, 2020, no first three 2020, Also, the investor in the 2019 2020 first 2021 February 15, 2021. Promissory Note Repayment On March 1, 2021, February 23, 2021, 2018 2019 2020

Note 6 - Stockholders' Equity,

Note 6 - Stockholders' Equity, Stock Options and Warrants	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 6 STOCKHOLDERS EQUITY, STOCK OPTIONS AND WARRANTS Equity Line On October 24, 2019, three three may September 30, 2021, During the three September, 30, 2021, not nine September 30, 2021, 2021 In June 2021, August 17, 2021. August 17, 2024. The Company paid to the placement agent a fee equal to 7.5% of the gross proceeds received by the Company in the offering and a management fee equal to 1% of the gross proceeds received by the Company in the offering and reimbursed the placement agent for $65,000 of non-accountable and out-of-pocket expenses. The Company also agreed to pay the placement agent $15,950 for clearing fees. Also, in connection with the offering, the Company agreed to grant the placement agent, or its designees warrants to purchase an aggregate of up to of 1,164,068 shares of its common stock (which represents 7.5% August 17, 2021 August 17, 2024. In January February 2021, five first four one two four one two five one five five one Offering Closing Date Shares Sale Price per Share* Investor Warrants Exercise Price per Share Investor Warrants Placement Agent Warrants Exercise Price per Share Placement Agent Warrants Gross Proceeds of Offering Net Proceeds of Offering January 12, 2021 (registered direct) 3,650,840 $ 0.842 1,825,420 $ 0.80 273,813 $ 1.0525 $ 3,074,007 $ 2,731,766 January 21, 2021 (registered direct) 2,200,000 $ 1.00 1,100,000 $ 1.00 165,000 $ 1.25 $ 2,200,000 $ 1,932,050 January 26, 2021 (registered direct) 3,414,970 $ 1.20 1,707,485 $ 1.37 256,123 $ 1.50 $ 4,097,964 $ 3,668,687 February 16, 2021 (registered direct) 4,222,288 $ 1.75 2,111,144 $ 2.00 316,672 $ 2.1875 $ 7,389,004 $ 6,679,989 February 23, 2021 (private placement) 9,043,766 $ 1.95 4,521,883 $ 2.00 678,282 $ 2.4375 $ 17,635,344 $ 16,064,739 Total 22,531,864 11,265,932 1,689,890 $ 34,396,319 $ 31,077,231 * one one 2021 During the period January 1, 2021 September 30, 2021, Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors, and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Shares Average Exercise Price Number of Shares Average Exercise Price Outstanding at December 31, 2019 766,424 $ 11.34 2,171,610 $ 15.26 Issued 319,851 1.03 8,097,468 1.55 Forfeited (72,728 ) 10.58 (128,710 ) 95.11 Exercised - - (2,786,992 ) 0.79 Outstanding at December 31, 2020 1,013,547 $ 5.41 7,353,376 $ 3.76 Issued 60,680 1.08 29,640,801 1.44 Forfeited (61,467 ) 9.27 - - Exercised - - (5,269,059 ) 0.86 Outstanding at September 30, 2021 1,012,760 $ 5.02 31,725,118 $ 2.08 Under the equity incentive plan, the Company is also authorized to issue restricted stock, restricted stock units (“RSUs”) and other awards specified under the plan. On August 10, 2021, 2012 nine September 30, 2021, January 1, 2024. nine September 30, 2021, September 30, 2021, Stock-based compensation expense recognized for three September 30, 2021 September 30, 2020 nine September 30, 2021 September 30, 2020 Dr. Carl Schwartz retired through his resignation as the Chief Executive Officer of the Company effective on March 19, 2021. April 1, 2021. On August 17, 2021,

Note 7 - Derivatives

Note 7 - Derivatives	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 7 DERIVATIVES Certain warrants issued to placement agents were determined to be a derivative liability due to certain features of the warrants which could, in certain circumstances, result in the holder receiving the Black Scholes value of the outstanding warrants in the same type of consideration as the common stockholders. As a result, in those circumstances, the amount of consideration would differ from that provided to holders of common stock, therefore, the warrants were classified as a liability. The fair value of the agent warrants issued in connection with the March 2020 December 31, 2020. nine September 30, 2021. September 30, 2021, The fair value of the agent warrants issued in connection with the May 2020 September 30, 2021 December 31, 2020, nine September 30, 2021. The placement agent warrants issued in connection with the June 2020 September 30, 2021 December 31, 2020, $44,051 nine September 30, 2021. The Company concluded the promissory note issued on February 5, 2020 815, Derivatives and Hedging two December 31, 2020, March 1, 2021, zero nine September 30, 2021. On September 30, 2020, September 2019 2019” 2019 815, Derivatives and Hedging December 31, 2020, March 1, 2021, zero nine September 30, 2021. The table below discloses changes in value of the Company’s embedded derivative liabilities discussed above. Derivative liability balance at December 31, 2019 $ 50,989 Derivative instrument recognized for A, B and Agent Warrants 2,669,995 Derivative instrument related to Promissory Note 2020 120,921 Gain recognized to revalue derivative instrument at fair value (27,107 ) Derivative liability balance at March 30, 2020 $ 2,814,798 Derivative instrument recognized for May 2020 Warrants 1,324,184 Derivative instrument recognized for June 2020 Warrants 1,749,721 Derivative instrument related to Promissory Note 2020 20,542 Reclassification of Warrant liabilities to Equity on exercise (1,701,756 ) Loss recognized to revalue derivative instrument at fair value 422,081 Derivative liability balance at June 30, 2020 $ 4,629,570 Gain recognized to revalue derivative instrument at fair value (1,402,768 ) Reclassification of Warrant liabilities to Equity (2,669,408 ) Derivative instrument related to September 30 debt amendments 495,100 Derivative liability balance at September 30, 2020 $ 1,052,494 Gain recognized to revalue derivative instrument at fair value (758,112 ) Derivative liability balance at December 31, 2020 $ 294,382 Gain recognized to revalue derivative instrument at fair value (95,671 ) Derivative liability balance at March 31, 2021 $ 198,711 Loss recognized to revalue derivative instrument at fair value 30,909 Derivative liability balance at June 30, 2021 $ 229,620 Gain recognized to revalue derivative instrument at fair value (4,122 ) Derivative liability balance at September 30, 2021 $ 225,498

Note 8 - Loss Per Share

Note 8 - Loss Per Share	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 8 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (5,438,017 ) $ (6,862,013 ) $ (11,900,662 ) $ (14,968,708 ) Denominator: Weighted average common shares outstanding-basic (1) 65,406,312 15,026,789 51,272,960 9,935,738 Effect of diluted stock options, warrants, and preferred stock (2) - - - - Weighted average common shares outstanding - diluted 65,406,312 15,026,789 51,272,960 9,935,738 Loss per common share-basic $ (0.08 ) $ ( 0.46 ) $ (0.23 ) $ (1.51 ) Loss per common share- diluted $ (0.08 ) $ ( 0.46 ) $ (0.23 ) $ (1.51 ) ( 1 The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Nine Months ended September 30, 2021 2020 Options 1,012,760 836,655 Warrants 31,725,118 7,257,883 RSU 516,666 - Convertible debt - 3,319,903 Preferred stock: series B 79,246 79,246

Note 9 - Segments

Note 9 - Segments	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 9 SEGMENTS The Company has determined its operating segments in accordance with ASC 280 Segment Reporting The Company has three operating segments: Skyline, Helomics and Soluble. See discussion of revenue recognition in Note 1 Summary of Significant Accounting Policies three nine September 30, 2021 Revenue Three Months Ended, Nine Months Ended, September 30, September 30, 2021 2020 2021 2020 Skyline $ 282,675 $ 471,054 $ 853,063 $ 924,605 Helomics 2,164 9,703 11,314 33,879 Soluble 27,653 - 76,639 - Corporate 1,171 - 3,171 - Total $ 313,663 $ 480,757 $ 944,187 $ 958,484 Segment Loss Three Months Ended, Nine Months Ended, September 30, September 30, 2021 2020 2021 2020 Skyline $ (102,850 ) $ (42,275 ) $ (378,490 ) $ (1,024,786 ) Helomics (3,739,275 ) (4,138,459 ) (6,024,129 ) (7,346,236 ) Soluble (352,324 ) (282,150 ) (840,790 ) (397,887 ) Corporate (1,243,568 ) (1,844,842 ) (4,657,253 ) (5,645,512 ) Total $ (5,438,017 ) $ (6,307,726 ) $ (11,900,662 ) $ (14,414,421 ) Assets As of September 30, As of December 31, 2021 2020 Skyline $ 860,408 $ 1,191,439 Helomics 6,184,782 9,773,902 Soluble 1,690,018 1,883,585 Corporate 42,454,902 211,510 Total $ 51,190,110 $ 13,060,436

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 10 RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company’s former directors, Richard L. Gabriel, is the Chief Operating Officer of GLG Pharma (“GLG”) and serves as a director of that firm. The Company and GLG have a partnership agreement for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no Richard L. Gabriel was also contracted as the Chief Operating Officer for TumorGenesis. Through April 1, 2019, six May 1, 2019, one three Effective May 1, 2021, not

Note 11 - Subsequent Events

Note 11 - Subsequent Events	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 11 SUBSEQUENT EVENTS Equity Line Agreement: fourth 2021 November 10, 2021

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Predictive Oncology Inc. (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 13, 2019. The Company operates in three In addition, the Company’s wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), is developing the next generation, patient-derived tumor models for precision cancer therapy and drug development. TumorGenesis is presented as part of the condensed consolidated financial statements and is included in corporate in the Company’s segment reporting. During the first 2018, April 4, 2019, The Company had cash and cash equivalents of $41,771,515 as of September 30, 2021. September 30, 2021, October 2019, three September 30, 2021, In June 2021, 6 In January February 2021, March 1, 2021, September 2018, September 2019, February 2020 2021 6 The Company believes that its existing capital resources will be sufficient to support its operating plan for the next twelve may twelve
Effect of Covid-19 Pandemic [Policy Text Block]	Coronavirus Outbreak In March 2020, 19 not 19 19 2020 may 2020. fourth 2020, 19 may
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to the prior years’ condensed consolidated financial statements to conform to the current year presentation. The reclassifications had no
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents The Company considers all highly liquid instruments with maturities when purchased of three
Receivable [Policy Text Block]	Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the status of individual accounts. Amounts recorded in accounts receivable on the condensed consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance for doubtful accounts is maintained to provide for the estimated amount of receivables that will not 30 30 not September 30, 2021 December 31, 2020.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements As outlined in Accounting Standards Codification (“ASC”) 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 7 Derivatives
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Fixed assets are stated at cost less accumulated depreciation and amortization. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers, software, and office equipment 3 - 10 Leasehold improvements (1) 2 - 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 10 Demo equipment 3 ( 1 Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term. Upon retirement or sale of fixed assets, the cost and related accumulated depreciation or amortization are removed from the condensed consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Long-lived Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. Accumulated amortization is included in intangibles, net in the accompanying condensed consolidated balance sheets. The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment may not may not not The Company concluded there was no December 31, 2020. September 30, 2020. The Company concluded there was no impairment of its finite-lived assets as of December 31, 2020. 360. The Company concluded there was no September 30, 2021. 360.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill In accordance with ASC 350, Intangibles Goodwill and Other not December 31, may not To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first not may first 2017 04, Simplifying the Test for Goodwill Impairment 3 1 Note 4 Intangible Assets and Goodwill
Lessee, Leases [Policy Text Block]	Leases ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 not The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within the Skyline segment. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping, and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the Skyline reportable segment. Revenue from Clinical Testing The Precision Oncology Insights are clinical diagnostic testing comprised of the Company’s Tumor Drug Response Testing (formerly ChemoFx) and Genomic Profiling (formerly BioSpeciFx) tests. The Tumor Drug Response test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the Genomic Profiling test evaluates the expression of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics’ payment terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at one For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect less consideration than it originally estimated for a contract with a patient, it will account for the change as a decrease to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. Accounts receivable totaled $275,193 and $256,878 as of September 30, 2021 December 31, 2020, The Company’s deferred revenues related primarily to maintenance plans of $152,546 and $53,028 as of September 30, 2021 December 31, 2020, Practical Expedients The Company has elected the practical expedient not
Valuation and Accounting for Stock Options and Warrants, Policy [Policy Text Block]	Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility, and estimated term. The fair value of each option and warrant grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: For the nine months ended September 30, 2021 2020 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% - 89.6% 82.6% - 87% Risk-free interest rate 0.93% - 1.45% 0.13% - 1.78% Expected life (in years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% - 89.6% 82.6%-87% Risk-free interest rate 0.42% - 1.04% 0.135% - 0.79% Expected life (in years) 3 - 5.5 5 - 5.5
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs were $234,357 and $227,805 for the nine September 30, 2021 2020,
Other Expense Policy [Policy Text Block]	Other Expense Other expense consisted primarily of interest expense, payment premium, amortization of original issue discounts, and loss on debt extinguishment associated with the Company’s notes payable.
Offering Costs [Policy Text Block]	Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering unless such costs are deemed to be insignificant in which case they are expensed as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes 740” 740, There is no income tax provision in the accompanying condensed consolidated statements of net loss due to the cumulative operating losses that indicate a 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not Under Internal Revenue Code Section 382, may not not 382 may Tax years subsequent to 2017
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one zero
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no In June 2016, 2016 13, not 12b 2 1934, January 1, 2023.

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers, software, and office equipment 3 - 10 Leasehold improvements (1) 2 - 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 10 Demo equipment 3
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	For the nine months ended September 30, 2021 2020 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% - 89.6% 82.6% - 87% Risk-free interest rate 0.93% - 1.45% 0.13% - 1.78% Expected life (in years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% - 89.6% 82.6%-87% Risk-free interest rate 0.42% - 1.04% 0.135% - 0.79% Expected life (in years) 3 - 5.5 5 - 5.5

Note 2 - Inventories (Tables)

Note 2 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of September 30, 2021 As of December 31, 2020 Finished goods $ 222,898 $ 95,898 Raw materials 161,910 151,366 Work-In-Process 13,168 42,271 Total $ 397,976 $ 289,535

Note 3 - Fixed Assets (Tables)

Note 3 - Fixed Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of September 30, 2021 As of December 31, 2020 Computers, software, and office equipment $ 1,964,329 $ 1,862,669 Leasehold improvements 321,796 315,297 Laboratory equipment 3,402,586 2,811,012 Manufacturing tooling 108,955 108,955 Demo equipment 56,614 56,614 Total 5,854,280 5,154,547 Less: Accumulated depreciation and amortization (2,043,640 ) (1,331,847 ) Total Fixed Assets, Net $ 3,810,640 $ 3,822,700

Note 4 - Intangible Assets (Tab

Note 4 - Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of September 30, 2021 As of December 31, 2020 Gross Carrying Costs Accumulated Amortization Net Carrying Amount Gross Carrying Costs Accumulated Amortization Net Carrying Amount Patents & Trademarks $ 452,119 $ (225,182 ) $ 226,937 $ 401,421 $ (211,110 ) $ 190,311 Developed Technology 2,882,000 (360,249 ) 2,521,751 2,882,000 (252,175 ) 2,629,825 Customer Relationships 445,000 (370,833 ) 74,167 445,000 (259,583 ) 185,417 Tradename 398,000 (21,808 ) 376,192 398,000 (5,452 ) 392,548 Total $ 4,177,119 $ (978,072 ) $ 3,199,047 $ 4,126,421 $ (728,320 ) $ 3,398,101
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ending December 31, Expense 2021 $ 83,940 2022 224,511 2023 187,428 2024 187,428 2025 187,428 Thereafter 2,328,312 Total $ 3,199,047
Schedule of Goodwill [Table Text Block]	Goodwill balance at December 31, 2018 $ - Acquired 23,790,290 Impairment (8,100,000 ) Goodwill balance at December 31, 2019 $ 15,690,290 Impairment (12,876,498 ) Goodwill balance at December 31, 2020 $ 2,813,792 Goodwill balance at December 31, 2020 $ 2,813,792 Impairment (2,813,792 ) Goodwill balance at September 30, 2021 $ -

Note 5 - Notes Payable (Tables)

Note 5 - Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Short-term Debt [Table Text Block]	Due Date As of September 30, 2021 As of December 31, 2020 Promissory note 2019 March 31, 2021 $ - $ 1,490,833 Promissory note 2020 March 31, 2021 - 1,464,146 2018 Investor Loan March 31, 2021 - 1,721,776 Total Notes Payable, gross - 4,676,755 Less: Unamortized discount - (244,830 ) Total Notes Payable, net $ - $ 4,431,925

Note 6 - Stockholders' Equity_2

Note 6 - Stockholders' Equity, Stock Options and Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Sales of Stock [Table Text Block]	Offering Closing Date Shares Sale Price per Share* Investor Warrants Exercise Price per Share Investor Warrants Placement Agent Warrants Exercise Price per Share Placement Agent Warrants Gross Proceeds of Offering Net Proceeds of Offering January 12, 2021 (registered direct) 3,650,840 $ 0.842 1,825,420 $ 0.80 273,813 $ 1.0525 $ 3,074,007 $ 2,731,766 January 21, 2021 (registered direct) 2,200,000 $ 1.00 1,100,000 $ 1.00 165,000 $ 1.25 $ 2,200,000 $ 1,932,050 January 26, 2021 (registered direct) 3,414,970 $ 1.20 1,707,485 $ 1.37 256,123 $ 1.50 $ 4,097,964 $ 3,668,687 February 16, 2021 (registered direct) 4,222,288 $ 1.75 2,111,144 $ 2.00 316,672 $ 2.1875 $ 7,389,004 $ 6,679,989 February 23, 2021 (private placement) 9,043,766 $ 1.95 4,521,883 $ 2.00 678,282 $ 2.4375 $ 17,635,344 $ 16,064,739 Total 22,531,864 11,265,932 1,689,890 $ 34,396,319 $ 31,077,231
Share-based Payment Arrangement, Activity [Table Text Block]	Stock Options Warrants Number of Shares Average Exercise Price Number of Shares Average Exercise Price Outstanding at December 31, 2019 766,424 $ 11.34 2,171,610 $ 15.26 Issued 319,851 1.03 8,097,468 1.55 Forfeited (72,728 ) 10.58 (128,710 ) 95.11 Exercised - - (2,786,992 ) 0.79 Outstanding at December 31, 2020 1,013,547 $ 5.41 7,353,376 $ 3.76 Issued 60,680 1.08 29,640,801 1.44 Forfeited (61,467 ) 9.27 - - Exercised - - (5,269,059 ) 0.86 Outstanding at September 30, 2021 1,012,760 $ 5.02 31,725,118 $ 2.08

Note 7 - Derivatives (Tables)

Note 7 - Derivatives (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Derivative liability balance at December 31, 2019 $ 50,989 Derivative instrument recognized for A, B and Agent Warrants 2,669,995 Derivative instrument related to Promissory Note 2020 120,921 Gain recognized to revalue derivative instrument at fair value (27,107 ) Derivative liability balance at March 30, 2020 $ 2,814,798 Derivative instrument recognized for May 2020 Warrants 1,324,184 Derivative instrument recognized for June 2020 Warrants 1,749,721 Derivative instrument related to Promissory Note 2020 20,542 Reclassification of Warrant liabilities to Equity on exercise (1,701,756 ) Loss recognized to revalue derivative instrument at fair value 422,081 Derivative liability balance at June 30, 2020 $ 4,629,570 Gain recognized to revalue derivative instrument at fair value (1,402,768 ) Reclassification of Warrant liabilities to Equity (2,669,408 ) Derivative instrument related to September 30 debt amendments 495,100 Derivative liability balance at September 30, 2020 $ 1,052,494 Gain recognized to revalue derivative instrument at fair value (758,112 ) Derivative liability balance at December 31, 2020 $ 294,382 Gain recognized to revalue derivative instrument at fair value (95,671 ) Derivative liability balance at March 31, 2021 $ 198,711 Loss recognized to revalue derivative instrument at fair value 30,909 Derivative liability balance at June 30, 2021 $ 229,620 Gain recognized to revalue derivative instrument at fair value (4,122 ) Derivative liability balance at September 30, 2021 $ 225,498

Note 8 - Loss Per Share (Tables

Note 8 - Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (5,438,017 ) $ (6,862,013 ) $ (11,900,662 ) $ (14,968,708 ) Denominator: Weighted average common shares outstanding-basic (1) 65,406,312 15,026,789 51,272,960 9,935,738 Effect of diluted stock options, warrants, and preferred stock (2) - - - - Weighted average common shares outstanding - diluted 65,406,312 15,026,789 51,272,960 9,935,738 Loss per common share-basic $ (0.08 ) $ ( 0.46 ) $ (0.23 ) $ (1.51 ) Loss per common share- diluted $ (0.08 ) $ ( 0.46 ) $ (0.23 ) $ (1.51 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Nine Months ended September 30, 2021 2020 Options 1,012,760 836,655 Warrants 31,725,118 7,257,883 RSU 516,666 - Convertible debt - 3,319,903 Preferred stock: series B 79,246 79,246

Note 9 - Segments (Tables)

Note 9 - Segments (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended, Nine Months Ended, September 30, September 30, 2021 2020 2021 2020 Skyline $ 282,675 $ 471,054 $ 853,063 $ 924,605 Helomics 2,164 9,703 11,314 33,879 Soluble 27,653 - 76,639 - Corporate 1,171 - 3,171 - Total $ 313,663 $ 480,757 $ 944,187 $ 958,484 Three Months Ended, Nine Months Ended, September 30, September 30, 2021 2020 2021 2020 Skyline $ (102,850 ) $ (42,275 ) $ (378,490 ) $ (1,024,786 ) Helomics (3,739,275 ) (4,138,459 ) (6,024,129 ) (7,346,236 ) Soluble (352,324 ) (282,150 ) (840,790 ) (397,887 ) Corporate (1,243,568 ) (1,844,842 ) (4,657,253 ) (5,645,512 ) Total $ (5,438,017 ) $ (6,307,726 ) $ (11,900,662 ) $ (14,414,421 ) As of September 30, As of December 31, 2021 2020 Skyline $ 860,408 $ 1,191,439 Helomics 6,184,782 9,773,902 Soluble 1,690,018 1,883,585 Corporate 42,454,902 211,510 Total $ 51,190,110 $ 13,060,436

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Mar. 01, 2021	Oct. 24, 2019	Jun. 30, 2021	Oct. 31, 2019	Feb. 28, 2021	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Apr. 04, 2019	Mar. 31, 2018
Cash and Cash Equivalents, at Carrying Value, Ending Balance						$ 41,771,515	$ 41,771,515		$ 678,332
Long-term Debt, Total						0	0
Stock Issued During Period, Shares, New Issues (in shares)					22,531,864
Proceeds from Issuance or Sale of Equity, Total					$ 34,396,319
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs					$ 31,077,231			$ 5,057,919
Repayments of Debt							4,162,744	1,459,973
Accounts Receivable, Allowance for Credit Loss, Current						0	0		0
Accounts Receivable, after Allowance for Credit Loss, Total						275,193	275,193		256,878
Contract with Customer, Liability, Total						152,546	152,546		53,028
Research and Development Expense, Total							234,357	$ 227,805
Income Tax Expense (Benefit), Total							0
Unrecognized Tax Benefits, Ending Balance						0	0
Licensing Agreements [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total									$ 0
Debt Issued in September 2018, September, 2019, and February 2020 [Member]
Repayments of Debt	$ 5,906,802
June 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			15,520,911
Equity Line Purchase Agreement [Member]
Issuance or Sale of Equity, Can Be Raised		$ 15,000,000
Sale of Stock, Remaining Available Balance						$ 9,200,829	$ 9,200,829
Stock Issued During Period, Shares, New Issues (in shares)		104,651				0	572,504
Equity Line Purchase Agreement [Member] | Investor [Member]
Issuance or Sale of Equity, Can Be Raised				$ 15,000,000
Sale of Equity, Term (Year)				3 years
June 2021 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)			15,520,911
Shares Issued, Price Per Share (in dollars per share)			$ 1.375
Proceeds from Issuance or Sale of Equity, Total			$ 21,341,253
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs			$ 19,446,296
Helomics Holding Corp. [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage											25.00%
Business Acquisition, Percentage of Voting Interests Acquired										75.00%

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	9 Months Ended
	Sep. 30, 2021
Demo Equipment [Member]
Computers, software, and office equipment (Year)	3 years
Minimum [Member] | Office Equipment [Member]
Computers, software, and office equipment (Year)	3 years
Minimum [Member] | Leasehold Improvements [Member]
Computers, software, and office equipment (Year)	2 years	[1]
Minimum [Member] | Manufacturing Tooling [Member]
Computers, software, and office equipment (Year)	3 years
Minimum [Member] | Laboratory Equipment [Member]
Computers, software, and office equipment (Year)	4 years
Maximum [Member] | Office Equipment [Member]
Computers, software, and office equipment (Year)	10 years
Maximum [Member] | Leasehold Improvements [Member]
Computers, software, and office equipment (Year)	5 years	[1]
Maximum [Member] | Manufacturing Tooling [Member]
Computers, software, and office equipment (Year)	7 years
Maximum [Member] | Laboratory Equipment [Member]
Computers, software, and office equipment (Year)	10 years
[1]	Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Expected dividend yield	0.00%	0.00%
Expected life (in years) (Year)	10 years	10 years
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Minimum [Member]
Expected stock price volatility	84.80%	82.60%
Risk-free interest rate	0.93%	0.13%
Minimum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.848	0.826
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0042	0.00135
Minimum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	3	5
Maximum [Member]
Expected stock price volatility	89.60%	87.00%
Risk-free interest rate	1.45%	1.78%
Maximum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.896	0.87
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0104	0.0079
Maximum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.5	5.5

Note 2 - Inventories - Schedule

Note 2 - Inventories - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Finished goods	$ 222,898	$ 95,898
Raw materials	161,910	151,366
Work-In-Process	13,168	42,271
Total	$ 397,976	$ 289,535

Note 3 - Fixed Assets (Details

Note 3 - Fixed Assets (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Depreciation, Total	$ 237,742	$ 236,599	$ 720,736	$ 485,648

Note 3 - Fixed Assets - Schedul

Note 3 - Fixed Assets - Schedule of Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Property, Plant, and Equipment Gross	$ 5,854,280	$ 5,154,547
Less: Accumulated depreciation and amortization	(2,043,640)	(1,331,847)
Total Fixed Assets, Net	3,810,640	3,822,700
Office Equipment [Member]
Property, Plant, and Equipment Gross	1,964,329	1,862,669
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	321,796	315,297
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	3,402,586	2,811,012
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 56,614	$ 56,614

Note 4 - Intangible Assets (Det

Note 4 - Intangible Assets (Details Textual)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Apr. 04, 2019USD ($)	Dec. 31, 2018USD ($)
Amortization of Intangible Assets, Total	$ 83,619		$ 77,258	$ 249,752	$ 230,947
Goodwill, Ending Balance	0	$ 2,813,792		0		$ 2,813,792	$ 15,690,290		$ 0
Goodwill, Impairment Loss	2,813,792	$ 9,879,458	$ 2,997,000	2,813,792	$ 2,997,000	$ 12,876,498	$ 8,100,000
Goodwill, Impaired, Accumulated Impairment Loss	$ 23,790,290			$ 23,790,290
Measurement Input, Expected Cash Flow Term [Member]
Reporting Unit Measurement Input	10	10	20	10	20	10
Measurement Input, Long-term Revenue Growth Rate [Member]
Reporting Unit Measurement Input	4	4	3	4	3	4
Measurement Input, Discount Rate [Member]
Reporting Unit Measurement Input	15	14	25	15	25	14
Measurement Input, Risk Premium [Member]
Reporting Unit Measurement Input		1	10		10	1
Helomics Holding Corp. [Member]
Goodwill, Ending Balance								$ 23,790,290

Note 4 - Intangible Assets - Co

Note 4 - Intangible Assets - Components of Intangible Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accumulated Amortization	$ (978,072)	$ (728,320)
Net Carrying Amount	3,199,047
Total, Gross Carrying Costs	4,177,119	4,126,421
Total, Net Carrying Amount	3,199,047	3,398,101
Trade Names 1 [Member]
Tradename		398,000
Tradename		(5,452)
Tradename		392,548
Patents and Trademarks [Member]
Gross Carrying Costs	452,119	401,421
Accumulated Amortization	(225,182)	(211,110)
Net Carrying Amount	226,937	190,311
Developed Technology Rights [Member]
Gross Carrying Costs	2,882,000	2,882,000
Accumulated Amortization	(360,249)	(252,175)
Net Carrying Amount	2,521,751	2,629,825
Customer Relationships [Member]
Gross Carrying Costs	445,000	445,000
Accumulated Amortization	(370,833)	(259,583)
Net Carrying Amount	74,167	$ 185,417
Trade Names [Member]
Tradename	398,000
Tradename	(21,808)
Tradename	$ 376,192

Note 4 - Intangible Assets - Es

Note 4 - Intangible Assets - Estimated Future Amortization Expense (Details)	Sep. 30, 2021USD ($)
2021	$ 83,940
2022	224,511
2023	187,428
2024	187,428
2025	187,428
Thereafter	2,328,312
Total	$ 3,199,047

Note 4 - Intangible Assets - Go

Note 4 - Intangible Assets - Goodwill (Details) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Goodwill				$ 2,813,792	$ 15,690,290	$ 15,690,290	$ 0
Acquired							23,790,290
Impairment	$ (2,813,792)	$ (9,879,458)	$ (2,997,000)	(2,813,792)	$ (2,997,000)	(12,876,498)	(8,100,000)
Goodwill	$ 0	$ 2,813,792		$ 0		$ 2,813,792	$ 15,690,290

Note 5 - Notes Payable (Details

Note 5 - Notes Payable (Details Textual) - USD ($)	Mar. 01, 2021	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Repayments of Debt				$ 4,162,744	$ 1,459,973
Debt Issued in September 2018, September, 2019, and February 2020 [Member]
Repayments of Debt	$ 5,906,802
Conversion of 2018 Investor Loan into Common Stock [Member]
Debt Conversion, Original Debt, Amount			$ 267,328
Debt Conversion, Converted Instrument, Shares Issued (in shares)			170,000
Conversion of 2019 and 2020 Investor Promissory Notes into Common Stock [Member]
Debt Conversion, Original Debt, Amount		$ 514,011
Debt Conversion, Converted Instrument, Shares Issued (in shares)		1,107,544

Note 5 - Notes Payable - Notes

Note 5 - Notes Payable - Notes Payable (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Notes Payable, Gross	$ 0	$ 4,676,755
Less: Unamortized discount	0	(244,830)
Notes Payable	0	4,431,925
Promissory Note, One [Member]
Notes Payable, Gross	0	1,490,833
Promissory Note, Two [Member]
Notes Payable, Gross	0	1,464,146
Convertible Promissory Note [Member]
Notes Payable, Gross	$ 0	$ 1,721,776

Note 6 - Stockholders' Equity_3

Note 6 - Stockholders' Equity, Stock Options and Warrants (Details Textual) - USD ($)	Apr. 01, 2021	Oct. 24, 2019	Jun. 30, 2021	Feb. 28, 2021	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Aug. 17, 2021	Aug. 10, 2021	Dec. 31, 2020
Stock Issued During Period, Shares, New Issues (in shares)				22,531,864
Proceeds from Issuance or Sale of Equity, Total				$ 34,396,319
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs				$ 31,077,231					$ 5,057,919
Sale of Stock, Agent Placement Fee, Percent of Gross Proceeds				7.50%
Sale of Stock, Management Fee, Percent of Gross Proceeds				1.00%
Proceeds from Warrant Exercises								$ 4,513,860	1,935,854
Share-based Payment Arrangement, Expense					$ 29,004		$ 134,675	$ 627,329	$ 557,452
Common Stock, Shares Authorized (in shares)			100,000,000		200,000,000			200,000,000		200,000,000		100,000,000
Dr. Carl Schwartz [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)	100,000
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount					$ 7,357			$ 7,357
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Month)								23 months
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)								450,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)								333,334
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)					516,666			516,666
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount					$ 122,162			$ 122,162
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Month)								27 months
Restricted Stock Units (RSUs) [Member] | Dr. Carl Schwartz [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)	300,000
Maximum [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)								3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)								10 years
Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)								3 years
Stock Incentive Plan 2012 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)			1,500,000								3,250,000
June 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			15,520,911
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 1.25
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,164,068
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 1.71875
Warrant Exercise Price, Percentage of Public Offering Price Per Share			125.00%
Sale of Stock, Placement Agent, Warrants Assigned, Number of Securities Called by Warrants, Percent of Shares Sold				7.50%
Class of Warrant or Right, Exercise Price of Warrants or Rights, Percent of Stock Price				125.00%
Investor Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.86			$ 0.86
Stock Issued During Period, Shares, Warrant Exercises (in shares)								5,269,059
Proceeds from Warrant Exercises								$ 4,513,860
Equity Line Purchase Agreement [Member]
Issuance or Sale of Equity, Can Be Raised		$ 15,000,000
Stock Issued During Period, Shares, New Issues (in shares)		104,651			0			572,504
Stock Issued During Period, Value, New Issues		$ 450,000						$ 588,590
Sale of Stock, Remaining Available Balance					$ 9,200,829			$ 9,200,829
June 2021 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)			15,520,911
Shares Issued, Price Per Share (in dollars per share)			$ 1.375
Proceeds from Issuance or Sale of Equity, Total			$ 21,341,253
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs			$ 19,446,296
Sale of Stock, Agent Placement Fee, Percent of Gross Proceeds			7.50%
Sale of Stock, Management Fee, Percent of Gross Proceeds			1.00%
Placement Agent Offering Fees			$ 65,000
Placement Agent, Clearing Fees			$ 15,950
Registered Direct Offerings [Member]
Stock Issued During Period, Value, New Issues						$ 15,012,492
Number of Warrants Issued to Each Investor, Per Two Shares of Stock Purchased (in shares)				1
Registered Direct Offerings [Member] | Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)				5 years
Registered Direct Offerings [Member] | Investor Warrants [Member]
Warrants and Rights Outstanding, Term (Year)				5 years 6 months
Private Placement [Member]
Stock Issued During Period, Value, New Issues						$ 16,064,739
Number of Warrants Issued to Each Investor, Per Two Shares of Stock Purchased (in shares)				1
Private Placement [Member] | Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)				5 years 6 months

Note 6 - Stockholders' Equity_4

Note 6 - Stockholders' Equity, Stock Options and Warrants - Stock Offerings (Details) - USD ($)		2 Months Ended	9 Months Ended
		Feb. 28, 2021	Sep. 30, 2020	Sep. 30, 2021	Jun. 30, 2021
Shares issued (in shares)		22,531,864
Gross proceeds		$ 34,396,319
Net proceeds		$ 31,077,231	$ 5,057,919
Investor Warrants [Member]
Warrants issued (in shares)		11,265,932
Warrants issued, exercise price (in dollars per share)				$ 0.86
Placement Agent Warrants [Member]
Warrants issued (in shares)		1,689,890
Warrants issued, exercise price (in dollars per share)					$ 1.71875
January 12, 2021 Registered Direct Offering [Member]
Shares issued (in shares)		3,650,840
Shares issued, price per share (in dollars per share)	[1]	$ 0.842
Gross proceeds		$ 3,074,007
Net proceeds		$ 2,731,766
January 12, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)		1,825,420
Warrants issued, exercise price (in dollars per share)		$ 0.80
January 12, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)		273,813
Warrants issued, exercise price (in dollars per share)		$ 1.0525
January 21, 2021 Registered Direct Offering [Member]
Shares issued (in shares)		2,200,000
Shares issued, price per share (in dollars per share)	[1]	$ 1
Gross proceeds		$ 2,200,000
Net proceeds		$ 1,932,050
January 21, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)		1,100,000
Warrants issued, exercise price (in dollars per share)		$ 1
January 21, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)		165,000
Warrants issued, exercise price (in dollars per share)		$ 1.25
January 26, 2021 Registered Direct Offering [Member]
Shares issued (in shares)		3,414,970
Shares issued, price per share (in dollars per share)	[1]	$ 1.20
Gross proceeds		$ 4,097,964
Net proceeds		$ 3,668,687
January 26, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)		1,707,485
Warrants issued, exercise price (in dollars per share)		$ 1.37
January 26, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)		256,123
Warrants issued, exercise price (in dollars per share)		$ 1.50
February 16, 2021 Registered Direct Offering [Member]
Shares issued (in shares)		4,222,288
Shares issued, price per share (in dollars per share)	[1]	$ 1.75
Gross proceeds		$ 7,389,004
Net proceeds		$ 6,679,989
February 16, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)		2,111,144
Warrants issued, exercise price (in dollars per share)		$ 2
February 16, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)		316,672
Warrants issued, exercise price (in dollars per share)		$ 2.1875
Febuary 23, 2021 Private Placement [Member]
Shares issued (in shares)		9,043,766
Shares issued, price per share (in dollars per share)	[1]	$ 1.95
Gross proceeds		$ 17,635,344
Net proceeds		$ 16,064,739
Febuary 23, 2021 Private Placement [Member] | Investor Warrants [Member]
Warrants issued (in shares)		4,521,883
Warrants issued, exercise price (in dollars per share)		$ 2
Febuary 23, 2021 Private Placement [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)		678,282
Warrants issued, exercise price (in dollars per share)		$ 2.4375
[1]	Sale price includes one share and a warrant to purchase one-half share.

Note 6 - Stockholders' Equity_5

Note 6 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Warrant [Member]
Number of Shares Outstanding (in shares)	7,353,376	2,171,610
Average Exercise Price Outstanding (in dollars per share)	$ 3.76	$ 15.26
Number of Shares Issued (in shares)	29,640,801	8,097,468
Average Exercise Price Issued (in dollars per share)	$ 1.44	$ 1.55
Number of Shares Forfeited (in shares)	0	(128,710)
Average Exercise Price Forfeited (in dollars per share)	$ 0	$ 95.11
Number of Shares Exercised (in shares)	(5,269,059)	(2,786,992)
Average Exercise Price Exercised (in dollars per share)	$ 0.86	$ 0.79
Number of Shares Outstanding (in shares)	31,725,118	7,353,376
Average Exercise Price Outstanding (in dollars per share)	$ 2.08	$ 3.76
Share-based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	1,013,547	766,424
Average Exercise Price Outstanding (in dollars per share)	$ 5.41	$ 11.34
Number of Shares Issued (in shares)	60,680	319,851
Average Exercise Price Issued (in dollars per share)	$ 1.08	$ 1.03
Number of Shares Forfeited (in shares)	(61,467)	(72,728)
Average Exercise Price Forfeited (in dollars per share)	$ 9.27	$ 10.58
Number of Shares Exercised (in shares)	0	0
Average Exercise Price Exercised (in dollars per share)	$ 0	$ 0
Average Exercise Price Exercised (in dollars per share)	$ 0	$ 0
Number of Shares Outstanding (in shares)	1,012,760	1,013,547
Average Exercise Price Outstanding (in dollars per share)	$ 5.02	$ 5.41

Note 7 - Derivatives (Details T

Note 7 - Derivatives (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2021	Mar. 01, 2021	Dec. 31, 2020	Dec. 30, 2020	Dec. 13, 2020
Agent Warrants In Connection With March 2020 Private Placement [Member]
Derivative Liability, Total	$ 74,980		$ 33,654
Derivative, Gain (Loss) on Derivative, Net, Total	(41,326)
Agent Warrants Issued In connection With May 2020 Offering [Member]
Derivative Liability, Total	73,765				$ 33,819
Derivative, Gain (Loss) on Derivative, Net, Total	(39,946)
Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative Liability, Total	76,752			$ 32,701
Derivative, Gain (Loss) on Derivative, Net, Total	(44,051)
Promissory Note 2020 Conversion Feature [Member]
Derivative Liability, Total		$ 0	104,529
Derivative, Gain (Loss) on Derivative, Net, Total	104,529
Promissory Note 2019 Conversion Feature Agent Warrants [Member]
Derivative Liability, Total		$ 0	$ 89,680
Derivative, Gain (Loss) on Derivative, Net, Total	$ 89,680

Note 7 - Derivatives - Change i

Note 7 - Derivatives - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Derivative liability balance	$ 229,620	$ 198,711	$ 294,382	$ 1,052,494	$ 4,629,570	$ 2,814,798	$ 50,989
Gain (loss) recognized to revalue derivative instrument at fair value	(4,122)	30,909	(95,671)	(758,112)	(1,402,768)	422,081	(27,107)
Reclassification of Warrant liabilities to Equity on exercise					(2,669,408)	(1,701,756)
Derivative liability balance	$ 225,498	$ 229,620	$ 198,711	$ 294,382	1,052,494	4,629,570	2,814,798
A, B and Agent Warrants [Member]
Derivative instrument recognized							2,669,995
Promissory Note 2020 [Member]
Derivative instrument recognized							$ 120,921
Warrant Issued in Connection With May 2020 Offering [Member]
Derivative instrument recognized						1,324,184
June 2020 Warrant [Member]
Derivative instrument recognized						1,749,721
Promissory Note 2020 2 [Member]
Derivative instrument recognized						$ 20,542
Warrants and Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative instrument recognized					$ 495,100

Note 8 - Loss Per Share - Share

Note 8 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net loss attributable to common shareholders per common share: basic and diluted calculation		$ (5,438,017)	$ (6,862,013)	$ (11,900,662)	$ (14,968,708)
Weighted average common shares outstanding-basic (1) (in shares)	[1]	65,406,312	15,026,789	51,272,960	9,935,738
Effect of diluted stock options, warrants, and preferred stock (2) (in shares)		0	0	0	0
Weighted average common shares outstanding - diluted (in shares)		65,406,312	15,026,789	51,272,960	9,935,738
Loss per common share-basic (in dollars per share)		$ (0.08)	$ (0.46)	$ (0.23)	$ (1.51)
Loss per common share- diluted (in dollars per share)		$ (0.08)	$ (0.46)	$ (0.23)	$ (1.51)
[1]	The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive:

Note 8 - Loss Per Share - Antid

Note 8 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	1,012,760	836,655
Warrant [Member]
Antidilutive Securities (in shares)	31,725,118	7,257,883
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities (in shares)	516,666	0
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	0	3,319,903
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	79,246	79,246

Note 9 - Segments (Details Text

Note 9 - Segments (Details Textual)	9 Months Ended
	Sep. 30, 2021
Number of Operating Segments	3

Note 9 - Segments - Segments (D

Note 9 - Segments - Segments (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Revenue	$ 313,663			$ 480,757			$ 944,187	$ 958,484
Net loss	(5,438,017)	$ (2,573,932)	$ (3,888,713)	(6,307,726)	$ (3,577,378)	$ (4,529,317)	(11,900,662)	(14,414,421)
Assets	51,190,110						51,190,110		$ 13,060,436
Corporate, Non-Segment [Member]
Revenue	1,171			0			3,171	0
Net loss	(1,243,568)			(1,844,842)			(4,657,253)	(5,645,512)
Assets	42,454,902						42,454,902		211,510
Skyline [Member] | Operating Segments [Member]
Revenue	282,675			471,054			853,063	924,605
Net loss	(102,850)			(42,275)			(378,490)	(1,024,786)
Assets	860,408						860,408		1,191,439
Helomics Segment [Member] | Operating Segments [Member]
Revenue	2,164			9,703			11,314	33,879
Net loss	(3,739,275)			(4,138,459)			(6,024,129)	(7,346,236)
Assets	6,184,782						6,184,782		9,773,902
Soluble [Member] | Operating Segments [Member]
Revenue	27,653			0			76,639	0
Net loss	(352,324)			$ (282,150)			(840,790)	$ (397,887)
Assets	$ 1,690,018						$ 1,690,018		$ 1,883,585

Note 10 - Related Party Trans_2

Note 10 - Related Party Transactions (Details Textual) - USD ($)	May 01, 2019	Apr. 01, 2019
Director [Member]
Related Party Transaction, Monthly Cash Payment	$ 13,500	$ 12,000

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - USD ($)	Oct. 24, 2019	Nov. 05, 2021	Feb. 28, 2021	Sep. 30, 2021	Sep. 30, 2021
Stock Issued During Period, Shares, New Issues (in shares)			22,531,864
Equity Line Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	104,651			0	572,504
Stock Issued During Period, Value, New Issues	$ 450,000				$ 588,590
Equity Line Purchase Agreement [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)		75,000
Stock Issued During Period, Value, New Issues		$ 87,000